A first-in-class biologic drug, an AXL-Fc fusion protein which acts as a trap for Gas6 AXL signaling which plays an important role tumor metastasis and associated EMT mechanism.
Total raised: $10M
Investors 2
| Date | Name | Website |
| - | 3E Biovent... | 3ebiovc.co... |
| - | Eshelman V... | eshelmanve... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 04.01.2022 | - | $10M | Eshelman V... | globenewsw... |
Mentions in press and media 8
| Date | Title | Description | Category | Author | Source |
| 04.01.2022 | Aravive An... | HOUSTON, Jan. 03, 2022 (GLOBE ... | - | - | marketscre... |
| 04.01.2022 | Aravive : ... | Aravive Announces $10.0 Millio... | - | - | marketscre... |
| 03.01.2022 | Aravive An... | HOUSTON, Jan. 03, 2022 (GLOBE ... | - | - | globenewsw... |
| 12.11.2021 | Aravive An... | 7 of 16 (44%) patients achieve... | - | - | marketscre... |
| 12.11.2021 | Aravive An... | Aravive Announces Positive Pre... | - | - | marketscre... |
| 09.11.2021 | Aravive An... | Aravive Announces Positive Pre... | - | - | marketscre... |
| 09.11.2021 | Aravive An... | 3 of 5 (60%) patients achieved... | - | - | marketscre... |
| 07.05.2013 | Arav Recei... | Arav, a near Naples, Italy-bas... | Italy mid... | - | finsmes.co... |